Live Breaking News & Updates on Therapeutic area strategy

Stay informed with the latest breaking news from Therapeutic area strategy on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Therapeutic area strategy and stay connected to the pulse of your community

J&J: EU marketing authorization application for Rybrevant -December 22, 2023 at 09:01 am EST

Johnson & Johnson announces that it has submitted a marketing authorization application to the European Medicines Agency seeking approval of lazertinib + Rybrevant for the first-line treatment of...

Catherine-taylor , European-medicines-agency , Johnson , Vice-president-medical-affairs , Therapeutic-area-strategy , Markets ,

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

/PRNewswire/ -- CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin...

Switzerland , Australia , Melbourne , Victoria , Steve-pascoe , Vifor-international , Fresenius-medical-care , Dual-endothelin-angiotensin-receptor-antagonist , Senior-vice-president , Therapeutic-area-strategy , Efficacy-endpoints , Two-year-exploratory-endpoints

Vifor International AG (CSL Vifor): Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment

Switzerland , Australia , Melbourne , Victoria , Steve-pascoe , Fresenius-medical-care , Dual-endothelin-angiotensin-receptor-antagonist , Senior-vice-president , Therapeutic-area-strategy , Efficacy-endpoints , Two-year-exploratory-endpoints , Travere-therapeutics

Amy Mahery, Author at MedCity News

Amy Mahery, Author at MedCity News
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Amy-mahery , Execution-leadership-team , Leadership-team , International-leadership-team , Serono , Trinity-college , Diversity-council , Global-business-franchise , Therapeutic-area-strategy , Chief-marketing-officer-leadership-team ,

Europe approves Ponvory (ponesimod) for multiple sclerosis

Europe approves Ponvory (ponesimod) for multiple sclerosis
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Norway , Iceland , Liechtenstein , United-kingdom , Gavin-giovannoni , Catherine-taylor , Janssen-ponvory , European-union , European-medicines-agency , European-commission , Drug-administration , Committee-for-medicinal-products-human-use

Janssen: Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Findings to be presented at the ASCO Annual Meeting show preliminary efficacy in patients with EGFR-mutated NSCLC and Janssen's commitment to address the need for new targeted therapies for this patient

United-states , Italy , Seoul , Soult-ukpyolsi , South-korea , United-kingdom , Mariotto , Puglia , France , French , American , Noah-reymond